Novanta reports Q3 adjusted EPS 87c, consensus 82c

Reports Q3 revenue $247.8M, consensus $245.95M. “We exceeded our expectations for revenue, profit and Adjusted EPS growth in the third quarter, based on improving business fundamentals, strength of continued new product revenues and significant growth in our Advanced Surgery business. In addition, we achieved a book-to-bill of 1.03x and saw 17% bookings growth year-over-year,” said Matthijs Glastra, Chair and Chief Executive Officer. “We are proud of our teams’ execution in achieving these results as we have been successfully navigating a complex macroenvironment.”